There is a particular kind of optimism required to put a robot in an operating room. The machine must be sophisticated; the experience of using it must feel almost ordinary. Melissa Teran spent the first decade of her career learning that distinction. Today, as CEO and co-founder of Alife Health, the machinery is software and the room is a fertility clinic, but the essential question has barely changed: how do you introduce powerful technology without asking professionals to suspend their judgment?
Teran’s answer begins with an engineer’s respect for systems. She studied materials science and engineering at the University of Michigan, then earned a master’s degree in systems engineering from Johns Hopkins. Materials science teaches that performance emerges from structure. Systems engineering teaches that the parts behave differently once connected. Her career would place her repeatedly at that intersection, where a promising component has to become a dependable whole.
She began in orthopedic surgical robotics at MAKO Surgical, working on systems intended to improve the placement of implants. MAKO was acquired by Stryker for $1.65 billion in 2013. Teran continued at Stryker Robotics, then moved west to Auris Health, where she managed systems engineering and user-experience design. Auris was building a robotic platform for endoscopic procedures. The company moved from zero to commercial in four years and was acquired by Johnson & Johnson for roughly $3.4 billion in 2019.
The price tags are memorable. The apprenticeship matters more. Teran worked where mechanical engineering, software, clinical practice, industrial design, and regulatory demands meet. She saw products tested against something tougher than a pitch deck: a trained user with a job to do.
“Clinical scientific excellence is essential in any medical space.”Melissa Teran
The product is also the room
Auris sharpened Teran’s interest in user experience. In complex clinical technology, the interface is not decoration. It can determine whether an elegant system belongs in practice. Physicians and technicians already possess habits, language, tools, and finely calibrated instincts. New software enters that living arrangement like an unfamiliar dinner guest: usefulness gets it invited back.
Teran spent about a year at Johnson & Johnson after the Auris acquisition. Then the startup world called again. In 2020 she joined Alife at its inception. Paxton Maeder-York founded the company and became its first CEO; Teran became a founding member, Chief Operating Officer, and Head of Product. The early leadership group carried experience from robotics, machine learning, medical devices, and clinical product development.
Alife’s premise was that fertility clinics held valuable data but often lacked modern ways to turn it into consistent, timely decisions. The company began building a family of applications for physicians, embryologists, operators, and patients. Teran has compared the structure to Adobe Creative Cloud: not one all-knowing button, but several tools arranged around different people and moments.
That distinction is the useful bit. AI companies are often narrated as model stories: gather data, train system, improve metric. A clinical software company is also an anthropology story. Who clicks? Who checks? Who explains? What existing hardware sits on the bench? Which record system receives the result? What happens on a busy Monday when a colleague is absent?
Teran’s remit at Alife stretched across product, research, regulatory work, sales, and marketing. It sounds unusually broad until one notices that each function answers a different version of the same question: what must be true for this tool to be trusted?
Begin with the workflow
Study the hands, screens, constraints, and handoffs already present before asking anyone to change.
Publish the evidence
In a clinical market, credibility is built in trials, papers, and careful claims, not merely demos.
Integrate quietly
Existing microscopes, imaging systems, and records are part of the product environment.
Let trust compound
Visits, conferences, introductions, and founder-led demonstrations carry the product between institutions.
A CEO title after the work
On October 10, 2024, Alife announced that Teran would succeed Maeder-York as CEO while he moved to the board. He credited her leadership across product, research, regulatory work, sales, and marketing. The succession had the useful shape of a long handoff: four years of accumulated context, then the title.
Teran’s public response was measured. She said she wanted to build on the company’s foundation and continue driving innovation, growth, and success for customers, partners, and employees. No reinvention costume was required. She already knew the machinery from the inside.
The following two years produced a series of concrete milestones. Alife announced its first international Embryo Predict deployment in Mexico City in July 2025. By December, Teran said the platform was present in 46 clinics across six countries and touched 15 percent of U.S. IVF cycles. In May 2026, FutureLife agreed to adopt Alife’s broader platform across a European network spanning 16 countries.
That same month, the U.S. Food and Drug Administration cleared Embryo Predict, Alife’s software designed to provide adjunctive information to embryologists assessing certain embryo images. The clearance followed a multi-center randomized clinical trial. In July, First Fertility announced a network deployment beginning in Connecticut. A young company’s verbs had changed: from build and test to deploy and expand.
The glamour of a good integration
Teran’s most revealing comments are not prophecies. They concern clinic visits, congress booths, scientific publications, and Zoom demonstrations. Fertility technology is a compact, relationship-driven market. People know one another. Reputation arrives before the salesperson and stays after the meeting.
The company’s financing story reinforces the point. Alife announced a $22 million Series A in 2022, bringing its disclosed funding at the time to more than $30 million. The investor group included Union Square Ventures, Lux Capital, and Maveron. Their partners Rebecca Kaden, Deena Shakir, and Anarghya Vardhana later appeared alongside Maeder-York on Alife’s board. For Teran, those connections were not distant names on a cap table. They formed part of the working circle around a company moving from research toward a market.
Commercialization forced choices that research alone could postpone. A model might perform well, yet a laboratory could still decline to use it if image capture was awkward. A report might be accurate, yet fail if it arrived too late for the relevant conversation. A clinic network might admire the idea, yet wait for evidence from peers. Alife responded by making integration a visible part of its pitch: software that connects with microscopes and imaging systems already in use, produces records, and fits into established digital infrastructure.
Teran’s language around customers is similarly concrete. She has spoken about building early prototypes with clinics, refining the value proposition through pilots, and investing in relationships before turning on commercialization. In December 2025, she described winning a contract with US Fertility and rolling the software across much of its network. The next stops were not selected by a viral growth loop. They came through professional congresses, extended physician networks, direct visits, and demonstrations.
There is something appealingly unfashionable about this. The company makes artificial intelligence, but its distribution strategy includes walking through doors and explaining the work. Teran knows the vocabulary of deep learning and propensity matching. She also knows that a small professional field remembers who answered the difficult question without dodging it. Technology may compress a calculation; it does not compress credibility.
This creates a slower and perhaps healthier tempo for AI. Teran argues that some industries cannot move with the casual dynamism of consumer software. The delay offers time to understand where a model actually helps. Her formulation is neat: be flexible and nimble in execution, but unwavering in mission.
“You have to be flexible and nimble in your execution, but unwavering in your mission.”Melissa Teran
There is a founder lesson here worth stealing. When a product enters a high-trust environment, validation and integration are not chores surrounding the product. They are part of the product. The paper, the pilot, the audit trail, the training session, and the clean handoff all contribute to what the customer is buying.
Teran’s patents make the same story in miniature. She is named on work involving medical-instrument navigation and targeting, the physical design of a medical-instrument handle, and machine-learning methods at Alife. The objects change from hardware to algorithms. The preoccupation remains: connect information to a consequential human action with precision.
A systems engineer’s second act
The easy version of Teran’s biography is a clean pivot from surgical robots to fertility AI. The more interesting version is continuity. Her second act uses the same muscles as the first: listen to expert users, translate among disciplines, design for constraints, gather evidence, and carry a complex system across the awkward distance between prototype and practice.
She also represents a particular kind of founder-operator. Teran did not arrive at Alife with the ceremonial authority of the top title. She accumulated authority by holding the messy middle: roadmaps, regulatory requirements, customer conversations, research priorities, and commercial demands. When the CEO role came, it formalized work already underway.
The aspiration now is geographic as much as technical. Alife has described expansion in Europe, the United Kingdom, Latin America, and the United States. Teran has also predicted that robotic automation and AI will increasingly meet over the next five to ten years. For someone who began beside surgical machines, that future may feel less like science fiction than a reunion.
What she appears to be building, in the end, is not a spectacle. It is a habit: software consulted at the right moment, evidence visible to the right person, an additional signal placed beside professional judgment. Advanced technology becomes valuable when the room no longer has to rearrange itself around the novelty. Melissa Teran learned that with robots. At Alife, she is betting a company on it.
Keep reading